[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-congenital-ichthyoses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-congenital-ichthyoses":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100526566","phase-2-a-44-week-monocentric-open-study-assessing-the-efficacy-and-safety-of-deucravacitinib-in-adults-with-inflammatory-genodermatoses-100526566",false,"NCT06136403","A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses","GENEPID","Inclusion Criteria:\n\n* Subject has congenital skin fragility with skin and\u002For mucosal blisters, a clinical phenotype of EBS-sev and a laboratory confirmed diagnosis of EBS by KRT5 and\u002For 14 mutation (autosomal only) OR a clinical phenotype of inflammatory ichthyosis (IC) including keratinopathic ichthyosis due to KRT1\u002F10 mutation, ECI with identified genetic mutations (TGM5, NIPAL4, ABCA12, etc…).\n* Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS \\> 50\u002F128.\n\n  * Subject agrees not to use any topical therapies other than the investigator approved.\n\nExclusion Criteria:\n\n* Subjects with another form of ICI ie Netherton syndrome, Kid syndrome etc.\n* Infectious\u002FImmune-related Exclusions\n* Medical History and Concurrent Diseases","ALL","18 Years","99 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment.\n\nParticipants will take treatments and have to use bullets during the study period.",[27,28,29,30],"Epidermolysis Bullosa Simplex","Ichthyosis","Genodermatosis","Inflammatory Congenital Ichthyoses",[32],"deucravacitinib","RECRUITING","2025-07-31",{"date":36,"type":37},"2025-08-05","ACTUAL",{"date":39,"type":37},"2024-03-18",{"date":41,"type":21},"2026-10-12",{"name":43,"class":44},"Centre Hospitalier Universitaire de Nice","OTHER",2]